KRAS and neoplasm: When K-RAS mutations occur, the RAS protein continues to activate, resulting in continued activation of the signaling pathway, and the targeting EGFR inhibitor loses its inhibitory effect on tumor cell growth, so patients with K-RAS mutations do not benefit from cetuximab therapy.